Ken Griffin Genetic Technologies LTD Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.86 - $1.82 $1,038 - $2,198	1,208 New	1,208 $1,000
Q2 2022 Aug 15, 2022	BUY	$0.0 - $0.01 $0 - $241	24,159 Added 202.03%	36,117 $41,000
Q1 2022 May 16, 2022	SELL	$0.0 - $0.0 $0 - $0	-24,097 Reduced 66.83%	11,958 $24,000
Q4 2021 Feb 14, 2022	SELL	$0.0 - $0.01 $0 - $44	-4,417 Reduced 10.91%	36,055 $0
Q3 2021 Nov 15, 2021	BUY	$0.0 - $0.01 $0 - $136	13,620 Added 50.72%	40,472 $125,000

Q2 2021 Aug 16, 2021	SELL	$0.0 - $0.02 $0 - $1,562	-78,138 Reduced 74.42%	26,852 $0
Q1 2021 May 17, 2021	BUY	$0.0 - $0.01 $0 - $809	80,917 Added 336.13%	104,990 $438,000
Q4 2020 Feb 16, 2021	BUY	$0.0 - $0.0 $0 - $0	24,073 New	24,073 $87,000

Ticker GENE
Exchange OTC
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 15,389,900
Market Cap $21.5M
Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.